Statistics for Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
Total visits
| views | |
|---|---|
| Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) | 5 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 2 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:69933e4a-eddc-4961-95bb-a7d611a49fff | 36 |
| java.util.UUID:8aa2b0c6-6ddb-4494-9b24-2ece1be4d3d4 | 21 |
| BJD-184-437.pdf | 6 |
| java.util.UUID:b2231546-14f6-427f-93cc-93c06b194589 | 5 |
Top country views
| views | |
|---|---|
| United States | 4 |
| India | 1 |
Top city views
| views | |
|---|---|
| Bloomington | 2 |
| Hillsborough | 1 |